Pralatrexate and leucovorin exposure
| . | Pralatrexate (n = 35) . | Leucovorin (n = 34) . |
|---|---|---|
| No. of cycles started | ||
| n | 35 | 34 |
| Mean (SD) | 1.89 (1.568) | 1.91 (1.583) |
| Median | 1.00 | 1.00 |
| Min, max | 1.0, 6.0 | 1.0, 6.0 |
| Cumulative dose received (mg/m2) | ||
| n | 35 | 34 |
| Mean (SD) | 304.05 (285.064) | 1499.26 (1327.727) |
| Median | 180.00 | 900.00 |
| Min, max | 29.4, 1046.9 | 300.0, 5100.0 |
| Relative dose intensity (%) | ||
| n | 35 | 34 |
| Mean (SD) | 86.56 (22.004) | 95.76 (5.727) |
| Median | 98.68 | 100.00 |
| Min, max | 52.2, 130.0 | 85.0, 100.0 |
| Dose reduced (%) | ||
| n | 1 | 0 |
| AE | 1 (2.86) | - |
| Investigator decision | 1 (2.86) | - |
| Dose delayed (%) | ||
| n | 1 | 0 |
| Oral mucositis | 1 (2.86) | - |
| . | Pralatrexate (n = 35) . | Leucovorin (n = 34) . |
|---|---|---|
| No. of cycles started | ||
| n | 35 | 34 |
| Mean (SD) | 1.89 (1.568) | 1.91 (1.583) |
| Median | 1.00 | 1.00 |
| Min, max | 1.0, 6.0 | 1.0, 6.0 |
| Cumulative dose received (mg/m2) | ||
| n | 35 | 34 |
| Mean (SD) | 304.05 (285.064) | 1499.26 (1327.727) |
| Median | 180.00 | 900.00 |
| Min, max | 29.4, 1046.9 | 300.0, 5100.0 |
| Relative dose intensity (%) | ||
| n | 35 | 34 |
| Mean (SD) | 86.56 (22.004) | 95.76 (5.727) |
| Median | 98.68 | 100.00 |
| Min, max | 52.2, 130.0 | 85.0, 100.0 |
| Dose reduced (%) | ||
| n | 1 | 0 |
| AE | 1 (2.86) | - |
| Investigator decision | 1 (2.86) | - |
| Dose delayed (%) | ||
| n | 1 | 0 |
| Oral mucositis | 1 (2.86) | - |